Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Friday, October 30, 2026

⚡ Executive Takeaway

Thursday settled the week's argument from both directions. Lilly moved 53% more volume at realized prices 15% lower: the new standard gets paid in volume, not price, and the market paid 6.6% more for that trade. Merck showed the defensive version of the same rule. Keytruda alone shrank 5%, Keytruda with Qlex grew 6%, so the franchise is now funding its own replacement and keeping a point of growth as the fee. And Iovance showed the penalty clause: a response rate that matched its own year old interim, reorganized into retrospective subgroups, was worth a third of the company by the close.

The through line we set Monday, only new standards get paid, net of the franchise replaced, closes confirmed on two of its three tests. Merck's slide stopped at its own quarter, and Amgen carried its gain into next Tuesday's print; Summit's discount rides to November 14. Watch Friday's debuts: Aspen and Bambusa price into a market that just showed both of its hands.

🎯 The Market Prices a Precision Pivot

Iovance lost 35.4% of its value after reporting a 24.6% response rate it called positive, because the number matched its own year old interim and the registrational plan now runs through a biomarker selected subset. IOVA

💉 Lilly Raised Its Year by $5.5 Billion at the Midpoint

Eli Lilly grew revenue 39% to $24.4 billion and took 2026 guidance to $91 to 92 billion, on 53% more volume at 15% lower realized prices. LLY

Mounjaro reached $10.7 billion, up 65%, with sales outside the US nearly doubling, and Zepbound hit $5.4 billion, up 49%. Foundayo booked its first $184 million. GAAP EPS rose 16% to $7.22 even with $4.57 per share of acquired IPR&D from the AtaiBeckley and Curevo deals, and the performance margin outlook rose three points to 52.0 to 52.5%. On the call, per BioSpace, the company credited the Medicare GLP-1 Bridge program with 500,000 patients on Lilly obesity medicines, 80% of them new to incretins. The release restated no retatrutide filing timing, one day after the head to head readout. The stock closed up 6.6%.

💊 Keytruda Is Funding Its Own Replacement

Merck grew sales 5% to $18.1 billion and raised both guidance midpoints, and the quarter's real story was franchise math: Keytruda alone fell 5%, Keytruda plus the subcutaneous Qlex grew 6% to $8.6 billion. MRK

Keytruda Qlex contributed $830 million against $5 million a year ago, which is the subcutaneous conversion covering the decline of the infusion product it replaces, with a point of growth left over. Winrevair nearly doubled to $694 million and Gardasil rose 14%. The pipeline section did real work: the sac-TMT endometrial BLA was accepted with a June 15, 2027 PDUFA and Merck says it is hopeful for an earlier approval, Welireg plus Lenvima won FDA approval in kidney cancer, the intismeran melanoma program with Moderna printed a 42% cut in the risk of recurrence or death, and the I-DXd small cell BLA was quietly withdrawn. MRK closed up 3.8%, which is the through line's grade.

🧬 One BLA, Many Patients: FDA's Genome Editing Draft

FDA's new draft guidance lets individualized genome editing products add new variants to an existing license without counting as new products, as long as they sit inside a predefined individualized feature space. It was announced Tuesday; we verified the document tonight.

The October 2026 CBER draft, Individualized Human Genome Editing Products, is the license and lifecycle half of a two part framework whose evidence half, the plausible mechanism draft, arrived in February. The operative sentence: adding a new product variant within a predefined feature space should not be considered to result in a new product. For platform editors that means one BLA can cover a family of patient specific products that share an editing method.

BioPharma Dive, which reported the announcement Wednesday, relayed TD Cowen calling the approach plug and play and naming Prime Medicine a beneficiary, with Prime up 15% and Beam up 8% on Wednesday per the article. The docket number and comment deadline sit in a Federal Register notice we could not retrieve tonight; the Pro brief has the operational read.

🧫 Gilead Raised the Year and Spent It Too

Gilead raised 2026 product sales guidance to $31.0 to 31.3 billion after HIV sales grew 18% to $6.2 billion, and still guides to a full year loss per share because $12.4 billion of deal charges land in 2026. GILD

Third quarter product sales rose 13% to $8.3 billion, with Biktarvy up 10%, Descovy up 49% and Trodelvy up 42%, against cell therapy down 18%. The quarter also delivered an FDA approval for Bixlenvo, a bictegravir and lenacapavir single tablet regimen, a Phase 2 ulcerative colitis win for the oral alpha 4 beta 7 inhibitor emvistegrast, and a fourth deal of the year, PepStar's oral IL-23R program. The release crossed at 4:02 pm Eastern, after the close, so Friday is the first session that can price it.

💰 Two IPOs Price Into a Tape That Showed Its Hands

Aspen Neuroscience priced at $15.00 for $140.6 million gross and Bambusa upsized to $168.9 million at $16.00; both debut Friday on a tape that just cut a data stage cell therapy company by a third. ASPE | BBTX

Aspen, the autologous iPSC derived Parkinson's cell therapy company, sold 9,375,000 shares; Bambusa, building long acting bispecific antibodies for immunology, sold 10,555,555. Both close November 2. The evening also brought an earnings wave: Penumbra grew 15.6% and, citing the pending Boston Scientific acquisition, gave no guidance and held no call, while Stryker, Illumina, Dexcom, Exelixis, Biohaven, BridgeBio and ResMed all reported after the bell, with first reactions Friday. Amgen confirmed its own quarter for Tuesday, November 3, after the close.

📋 Quick Hits

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

📋 The Week in Review

Retatrutide beat the standard head to head. Iovance matched its own interim and lost a third.

Reply if your answer is not on the list.